z-logo
open-access-imgOpen Access
Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review
Author(s) -
Rumeng Gu,
Ziling Shi,
Ting Duan,
Meijun Song
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s334213
Subject(s) - alectinib , anaplastic lymphoma kinase , medicine , adenocarcinoma , crizotinib , alk inhibitor , lung cancer , oncology , tyrosine kinase inhibitor , cancer , malignant pleural effusion
Pulmonary invasive mucinous adenocarcinoma (IMA) is a rare variant of lung adenocarcinoma that rarely shows anaplastic lymphoma kinase (ALK) rearrangement. Alectinib (tyrosine kinase inhibitors) has been listed as category 1 recommendations for advanced ALK + NSCLC first-line therapy due to low toxicity and excellent efficacy, and its median progression-free survival is 34.8 months. Here, we report a case of a patient with ALK-rearranged lung IMA who showed favorable results to neoadjuvant alectinib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here